Trials / Completed
CompletedNCT00615017
AZD9773 Dose Escalation Study
A Placebo-controlled, Double-blind, Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients With Severe Sepsis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a double-blind, placebo-controlled, multi-center, dose-escalation study to assess the safety, tolerability, Pharmacokinetics and Pharmacodynamics of single and multiple ascending intravenous infusions of CytoFab (AZD9773) in adult patients with severe sepsis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD9773 (CytoFab) | intravenous infusions |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2008-02-14
- Last updated
- 2013-08-22
- Results posted
- 2013-08-22
Locations
26 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00615017. Inclusion in this directory is not an endorsement.